Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Bystander effect assay. Bystander killing effect was evaluated by admixing END(K)265 (3+ TROP2 expression) in vitro with carboxyfluorescein succinimidyl ester (CFSE)–stained END(K)34 cells (0 TROP2 expression). At dose 5 μg/mL, a significant increase in cytotoxicity of END(K)34 cells was seen when END(K)34 and END(K)265 were cultured together and treated with Dato-DXd when compared with ADC control–treated cocultures (P = 0.0167). In addition, a significant increase in cytotoxicity of END(K)34 cells was seen when the cocultures were treated with Dato-DXd as compared with isolated END(K)34 cells treated with Dato-DXd (P = 0.0329; *, P